参考文献/References:
[1] SIEGEL R L,MILLER K D,FUCHS H E,et al.Cancer statistics,2022[J].CA Cancer J Clin,2022,72(1):7-33.
[2] 钟亮,刘清壮,蔡茂德.Ⅲ、Ⅳ期上皮性卵巢癌术后腹腔辅助化疗临床观察[J].陕西医学杂志,2020,49(2):193-196.
[3] LI M,TAO Z,ZHAO Y,et al.5-methylcytosine RNA methyltransferases and their potential roles in cancer[J].J Transl Med,2022,20(1):214.
[4] HOPFINGER M C,KIRKPATRICK C C,ZNOSKO B M.Predictions and analyses of RNA nearest neighbor parameters for modified nucleotides[J].Nucleic Acids Res,2020,48(16):8901-8913.
[5] XIE S,CHEN W,CHEN K,et al.Emerging roles of RNA methylation in gastrointestinal cancers[J].Cancer Cell Int,2020,20(1):585.
[6] 韩永康,杜毓锋,钱力,等.N6-甲基腺苷修饰在呼吸系统疾病中的研究进展[J].陕西医学杂志,2024,53(1):136-139,144.
[7] FENG H,YUAN X,WU S,et al.Effects of writers,erasers and readers within miRNA-related m6A modification in cancers[J].Cell Prolif,2022,56(1):e13340.
[8] ZENG C,HUANG W,LI Y,et al.Roles of METTL3 in cancer:Mechanisms and therapeutic targeting[J].J Hematol Oncol,2020,13(1):117.
[9] DOU X,HUANG L,XIAO Y,et al.METTL14 is a chromatin regulator independent of its RNA N6-methyladenosine methyltransferase activity[J].Protein Cell,2023,14(9):683-697.
[10] PING X L,SUN B F,WANG L,et al.Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase[J].Cell Res,2014,24(2):177-189.
[11] PATIL D P,CHEN C K,PICKERING B F,et al.m6A RNA methylation promotes XIST-mediated transcriptional repression[J].Nature,2016,537(7620):369-373.
[12] SCHWARTZ S,MUMBACH M R,JOVANOVIC M,et al.Perturbation of m6A writers reveals two distinct classes of mRNA methylation at internal and 5' sites[J].Cell Rep,2014,8(1):284-296.
[13] WEN J,LV R,MA H,et al.Zc3h13 regulates nuclear RNA m6A methylation and mouse embryonic stem cell self-renewal[J].Mol Cell,2018,69(6):1028-1038.e6.
[14] AGUILO F,ZHANG F,SANCHO A,et al.Coordination of m6A mRNA methylation and gene transcription by ZFP217 regulates pluripotency and reprogramming[J].Cell Stem Cell,2015,17(6):689-704.
[15] LESBIREL S,WILSON S A.The m6A methylase complex and mRNA export[J].Biochim Biophys Acta Gene Regul Mech,2019,1862(3):319-328.
[16] DENG L J,DENG W Q,FAN S R,et al.m6A modification:Recent advances,anticancer targeted drug discovery and beyond[J].Mol Cancer,2022,21(1):52.
[17] JIA G,FU Y,ZHAO X,et al.N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO[J].Nat Chem Biol,2011,7(12):885-887.
[18] FANG Z,HU Y,HU J,et al.The crucial roles of N6-methyladenosine(m6A)modification in the carcinogenesis and progression of colorectal cancer[J].Cell Biosci,2021,11(1):72.
[19] GARCÍA-VÍLCHEZ R,SEVILLA A,BLANCO S.Post-transcriptional regulation by cytosine-5 methylation of RNA[J].Biochim Biophys Acta Gene Regul Mech,2019,1862(3):240-252.
[20] YANG X,YANG Y,SUN B F,et al.5-methylcytosine promotes mRNA export-NSUN2 as the methyltransferase and ALYREF as an m5C reader[J].Cell Res,2017,27(5):606-625.
[21] XU Y,ZHANG M,ZHANG Q,et al.Role of main RNA methylation in hepatocellular carcinoma:N6-methyladenosine,5-methylcytosine,and N1-methyladenosine[J].Front Cell Dev Biol,2021,9:767668.
[22] DAI X,WANG T,GONZALEZ G,et al.Identification of YTH domain-containing proteins as the readers for N1-methyladenosine in RNA[J].Anal Chem,2018,90(11):6380-6384.
[23] BI X,LV X,LIU D,et al.METTL3-mediated maturation of miR-126-5p promotes ovarian cancer progression via PTEN-mediated PI3K/Akt/mTOR pathway[J].Cancer Gene Ther,2021,28(3-4):335-349.
[24] HUANG H,WANG Y,KANDPAL M,et al.FTO-dependent N6-methyladenosine modifications inhibit ovarian cancer stem cell self-renewal by blocking cAMP signaling[J].Cancer Res,2020,80(16):3200-3214.
[25] EMMANUEL R,WEINSTEIN S,LANDESMAN-MILO D,et al.eIF3c:A potential therapeutic target for cancer[J].Cancer Lett,2013,336(1):158-166.
[26] LEE H Y,CHEN C K,HO C M,et al.EIF3C-enhanced exosome secretion promotes angiogenesis and tumorigenesis of human hepatocellular carcinoma[J].Oncotarget,2018,9(17):13193-13205.
[27] LI T,LI S,CHEN D,et al.Transcriptomic analyses of RNA-binding proteins reveal eIF3c promotes cell proliferation in hepatocellular carcinoma[J].Cancer Sci,2017,108(5):877-885.
[28] HU C,WANG Y,LI A,et al.Overexpressed circ_0067934 acts as an oncogene to facilitate cervical cancer progression via the miR-545/EIF3C axis[J].J Cell Physiol,2019,234(6):9225-9232.
[29] HERSHEY J W B.The role of eIF3 and its individual subunits in cancer[J].Biochim Biophys Acta,2015,1849(7):792-800.
[30] SPILKA R,ERNST C,MEHTA A K,et al.Eukaryotic translation initiation factors in cancer development and progression[J].Cancer Lett,2013,340(1):9-21.
[31] ZHANG S,PEI M,LI Z,et al.Double-negative feedback interaction between DNA methyltransferase 3A and microRNA-145 in the Warburg effect of ovarian cancer cells[J].Cancer Sci,2018,109(9):2734-2745.
[32] LI J,LI X,WU L,et al.MiR-145 inhibits glutamine metabolism through c-myc/GLS1 pathways in ovarian cancer cells[J].Cell Biol Int,2019,43(8):921-930.
[33] LI J,ZHANG S,ZOU Y,et al.MiR-145 promotes miR-133b expression through c-myc and DNMT3A-mediated methylation in ovarian cancer cells[J].J Cell Physiol,2020,235(5):4291-4301.
[34] MÜLLER S,GLASS M,SINGH A K,et al.IGF2BP1 promotes SRF-dependent transcription in cancer in a m6A- and miRNA-dependent manner[J].Nucleic Acids Res,2019,47(1):375-390.
[35] MÜLLER S,BLEY N,GLASS M,et al.IGF2BP1 enhances an aggressive tumor cell phenotype by impairing miRNA-directed downregulation of oncogenic factors[J].Nucleic Acids Res,2018,46(12):6285-6303.
[36] MEDJKANE S,PEREZ-SANCHEZ C,GAGGIOLI C,et al.Myocardin-related transcription factors and SRF are required for cytoskeletal dynamics and experimental metastasis[J].Nat Cell Biol,2009,11(3):257-268.
[37] MA Z,LI Q,LIU P,et al.METTL3 regulates m6A in endometrioid epithelial ovarian cancer independently of METTl14 and WTAP[J].Cell Biol Int,2020,44(12):2524-2531.
[38] SHEN Z,GU L,LIU Y,et al.PLAA suppresses ovarian cancer metastasis via METTL3-mediated m6A modification of TRPC3 mRNA[J].Oncogene,2022,41(35):4145-4158.
[39] ZHAO L,KONG X,ZHONG W,et al.FTO accelerates ovarian cancer cell growth by promoting proliferation,inhibiting apoptosis,and activating autophagy[J].Pathol Res Pract,2020,216(9):153042.
[40] CHAO Y,SHANG J,JI W.ALKBH5-m6A-FOXM1 signaling axis promotes proliferation and invasion of lung adenocarcinoma cells under intermittent hypoxia[J].Biochem Biophys Res Commun,2020,521(2):499-506.
[41] LI X C,JIN F,WANG B Y,et al.The m6A demethylase ALKBH5 controls trophoblast invasion at the maternal-fetal interface by regulating the stability of CYR61 mRNA[J].Theranostics,2019,9(13):3853-3865.
[42] JIN D,GUO J,WU Y,et al.m6A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2-mediated YAP activity in NSCLC[J].Mol Cancer,2020,19(1):40.
[43] JIANG Y,WAN Y,GONG M,et al.RNA demethylase ALKBH5 promotes ovarian carcinogenesis in a simulated tumour microenvironment through stimulating NF-κB pathway[J].J Cell Mol Med,2020,24(11):6137-6148.
[44] HONG L,WANG X,ZHENG L,et al.Tumor-associated macrophages promote cisplatin resistance in ovarian cancer cells by enhancing WTAP-mediated N6-methyladenosine RNA methylation via the CXCL16/CXCR6 axis[J].Cancer Chemother Pharmacol,2023,92(1):71-81.
[45] YU H L,MA X D,TONG J F,et al.WTAP is a prognostic marker of high-grade serous ovarian cancer and regulates the progression of ovarian cancer cells[J].Onco Targets Ther,2019,12:6191-6201.
[46] LONG J,ZHANG B,SIGNORELLO L B,et al.Evaluating genome-wide association study-identified breast cancer risk variants in African-American women[J].PLoS One,2013,8(4):e58350.
[47] LI J,GREGORY R I.Mining for METTL3 inhibitors to suppress cancer[J].Nat Struct Mol Biol,2021,28(6):460-462.
[48] SU R,DONG L,LI Y,et al.Targeting FTO suppresses cancer stem cell maintenance and immune evasion[J].Cancer Cell,2020,38(1):79-96.e11.
[49] SU R,DONG L,LI C,et al.R-2HG exhibits anti-tumor activity by targeting FTO/m6A/MYC/CEBPA signaling[J].Cell,2018,172(1-2):90-105.e23.
[50] 张媛,王莉华,郭燕,等.大黄酸对白血病细胞脂肪量 和肥胖相关蛋白表达及细胞增殖和凋亡的影响 [J].新乡医学院学报,2021,38(3):220-225.[51] 林增海,陆军,王凯松.槲皮素对5-FU诱导的结直肠癌SW480细胞耐药及自噬调控机制研究[J].陕西中医,2021,42(10):1338-1343.[52] 韩笑,王梦斐,蒲位凌,等.中药活性成分通过调节m6A甲基化修饰抗肿瘤的研究进展[J].中草药,2024,55(6):2123-2130.[53] WANG L,GAO S.Identification of 5-methylcytosine-related signature for predicting prognosis in ovarian cancer[J].Biol Res,2021,54(1):18.[54] CHEN Y T,SHEN J Y,CHEN D P,et al.Identification of cross-talk between m6A and 5mC regulators associated with onco-immunogenic features and prognosis across 33 cancer types[J].J Hematol Oncol,2020,13(1):22.[55] LIU X,WEI Q,YANG C,et al.RNA m5C modification upregulates E2F1 expression in a manner dependent on YBX1 phase separation and promotes tumor progression in ovarian cancer[J].Exp Mol Med,2024,56(3):600-615.[56] HUME D A,MACDONALD K P A.Therapeutic applications of macrophage colony-stimulating factor-1(CSF-1)and antagonists of CSF-1 receptor(CSF-1R)signaling[J].Blood,2012,119(8):1810-1820.[57] WOO H H,CHAMBERS S K.Human ALKBH3-induced m1A demethylation increases the CSF-1 mRNA stability in breast and ovarian cancer cells[J].Biochim Biophys Acta Gene Regul Mech,2019,1862(1):35-46.[58] LIU J,CHEN C,WANG Y,et al.Comprehensive of N1-methyladenosine modifications patterns and immunological characteristics in ovarian cancer[J].Front Immunol,2021,12:746647.
相似文献/References:
[1]刘瑞丽,刘小红,李会荣,等.主动循环腹腔热灌注化疗治疗卵巢癌伴腹腔积液效果观察*[J].陕西医学杂志,2019,(12):1630.
LIU Ruili,LIU Xiaohong,LI Huirong,et al.Curative effect of active circulation intraperitoneal hyperthermic perfusion chemotherapy on ovarian cancer combined with seroperitoneum and its influences on prognosis[J].,2019,(11):1630.
[2]高 燕,杨 红,刘淑娟,等.线粒体动态蛋白在卵巢癌中的表达及临床意义[J].陕西医学杂志,2021,50(12):1589.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.031]
GAO Yan,YANG Hong,LIU Shujuan,et al.Expression and clinical significance of mitochondrial dynamic protein of 51 kDa in ovarian cancer[J].,2021,50(11):1589.[doi:DOI:10.3969/j.issn.1000-7377.2021.12.031]
[3]段小霞,郭 华,付 婷,等.震颤同系物-5过表达对卵巢癌细胞A2780增殖和凋亡的影响[J].陕西医学杂志,2022,51(5):529.[doi:DOI:10.3969/j.issn.1000-7377.2022.05.004]
DUAN Xiaoxia,GUO Hua,FU Ting,et al.Effect of quaking homolog-5 overexpression on proliferation and apoptosis of ovarian cancer cell line A2780[J].,2022,51(11):529.[doi:DOI:10.3969/j.issn.1000-7377.2022.05.004]
[4]耿海慧,曹爱华.卵巢癌患者多种血清肿瘤标志物表达水平及其对疾病的诊断价值研究[J].陕西医学杂志,2022,51(7):886.[doi:DOI:10.3969/j.issn.1000-7377.2022.07.029]
GENG Haihui,CAO Aihua.Expression levels of various serum tumor markers in ovarian cancer patients and their diagnostic value for the disease[J].,2022,51(11):886.[doi:DOI:10.3969/j.issn.1000-7377.2022.07.029]
[5]王 静,张虹宇,张 磊,等.动脉灌注分数联合转化生长因子-β及上皮细胞钙黏蛋白检测对原发性卵巢癌的诊断价值研究[J].陕西医学杂志,2023,52(7):858.[doi:DOI:10.3969/j.issn.1000-7377.2023.07.019]
[6]王 静,张虹宇,张 磊,等.动脉灌注化疗联合细胞因子诱导杀伤细胞治疗晚期卵巢癌疗效及对患者血清癌胚抗原、糖类抗原125、可溶性B7-H4蛋白水平的影响[J].陕西医学杂志,2024,(2):199.[doi:DOI:10.3969/j.issn.1000-7377.2024.02.011]
WANG Jing,ZHANG Hongyu,ZHANG Lei,et al.Efficacy of arterial infusion chemotherapy combined with CIK in the treatment of advanced ovarian cancer and its effect on serum levels of carcinoembryonic antigen,carbohydrate antigen 125 and soluble B7-H4 protein[J].,2024,(11):199.[doi:DOI:10.3969/j.issn.1000-7377.2024.02.011]
[7]刘玉锋,薛芳芳.卵巢癌患者造血前B细胞白血病转录因子相互作用蛋白表达和术前中性粒细胞与淋巴细胞比值水平及其临床检测价值[J].陕西医学杂志,2024,(5):662.[doi:DOI:10.3969/j.issn.1000-7377.2024.05.019]
[8]冷小飞,张逸群,魏 峰,等.长链非编码RNA RP11-572P18.1对卵巢癌细胞增殖和侵袭的影响及作用机制实验研究[J].陕西医学杂志,2024,(8):1011.[doi:DOI:10.3969/j.issn.1000-7377.2024.08.001]
LENG Xiaofei,ZHANG Yiqun,WEI Feng,et al.Effect of long non-coding RNA RP11-572P18.1 on the proliferation and invasion of ovarian cancer cells and its mechanism[J].,2024,(11):1011.[doi:DOI:10.3969/j.issn.1000-7377.2024.08.001]
[9]司 晗,李洁妹,宗佳琪,等.高糖环境对卵巢癌细胞侵袭和迁移的影响及其机制实验研究[J].陕西医学杂志,2024,(8):1016.[doi:DOI:10.3969/j.issn.1000-7377.2024.08.002]
SI Han,LI Jiemei,ZONG Jiaqi,et al.Effect of high glucose environment on the invasion and migration of ovarian cancer cells and its mechanism[J].,2024,(11):1016.[doi:DOI:10.3969/j.issn.1000-7377.2024.08.002]
[10]王 静,张虹宇,张 磊,等.长链非编码RNA PVT1调控表皮生长因子受体/有丝分裂原活性蛋白激酶通路对卵巢癌细胞的影响实验研究[J].陕西医学杂志,2024,(11):1454.[doi:DOI:10.3969/j.issn.1000-7377.2024.11.003]
WANG Jing,ZHANG Hongyu,ZHANG Lei,et al.Effect of long non-coding RNA PVT1 on ovarian cancer cells by regulating epidermal growth factor receptor/mitogen-activated protein kinase pathway[J].,2024,(11):1454.[doi:DOI:10.3969/j.issn.1000-7377.2024.11.003]